Supplement With Calcium or Alendronate Suppresses Osteopenia Due to Long Term Rabeprazole Treatment in Female Mice: Influence on Bone TRAP and Osteopontin Levels

Supplement With Calcium or Alendronate Suppresses Osteopenia Due to Long Term Rabeprazole Treatment in Female Mice: Influence on Bone TRAP and Osteopontin Levels

Background and PurposeRabeprazole, a proton pump inhibitor (PPIs) is much endorsed to patients with increased gastric acidity. PPIs were accused to have osteoporotic effects on patients who chronically use them. The point of the current investigation was to decide the impact of rabeprazole on osteop...

Full description

Bibliographic Details
Main Authors: Aly A.M. Shaalan, Mohamed El-Sherbiny, Taghrid B. El-Abaseri, Mohamed Z. Shoaeir, Tarek M. Abdel-Aziz, Magda I. Mohamed, Sawsan A. Zaitone, Hala M. F. Mohammad
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-05-01
Series:Frontiers in Pharmacology
Subjects:
alendronate
calcium
osteopenia
osteopontin
rabeprazole
tartrate resistant acid phosphatase
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2020.00583/full

Similar Items

Similar Items